Abstract
We have treated animals with an ongoing autoimmune disease, experimental autoimmune myasthenia gravis (EAMG), using a strategy designed to eliminate the antibody-producing cells. During well-established EAMG, a single high dose of cyclophosphamide was given because of its known effectiveness against B-lymphocytes. To counteract the lethal effects of the drug, the rats were "rescued" by bone marrow cell transplantation. This treatment produced a rapid and sustained fall of antibody titers against both the immunizing antigen (Torpedo acetylcholine receptor) and the autoantigen (rat acetylcholine receptor). Immunologic memory, as measured by an anamnestic response to the antigen, was partially suppressed. Cyclophosphamide treatment produced improvement in the neuromuscular defect: treated animals had, on the average, twice as many acetylcholine receptors at neuromuscular junctions compared with untreated EAMG animals. This treatment method of short-term high doses of an immunosuppressive drug, such as cyclophosphamide, may eventually prove useful for human myasthenia gravis and other autoimmune diseases.
References
Dec 23, 1976·Nature·A PestronkJ W Griffin
Jan 19, 1978·The New England Journal of Medicine·D B Drachman
Apr 17, 1975·The New England Journal of Medicine·E ThomasC D Buckner
Jan 1, 1976·Drugs·J F Bach
Aug 1, 1975·Transplantation·P J Tutschka, G W Santos
Jan 20, 1977·The New England Journal of Medicine·K V ToykaI Kao
Nov 1, 1976·Neurology·J M LindstromD D Duane
Oct 9, 1975·The New England Journal of Medicine·S H AppelN Levy
Mar 25, 1976·The New England Journal of Medicine·T MittagC Woo
Jan 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·D K BergZ W Hall
Oct 1, 1974·The Journal of General Physiology·D M Fambrough
Nov 1, 1973·Archives of Biochemistry and Biophysics·M E Eldefrawi, A T Eldefrawi
May 8, 1980·The New England Journal of Medicine·K G BlumeJ L Wolf
Mar 27, 1980·The New England Journal of Medicine·P F CocciaD M Brown
Citations
Jan 2, 2003·Annals of Neurology·Daniel B DrachmanRobert A Brodsky
Sep 1, 1990·Journal of Neuroimmunology·S de SilvaD B Drachman
May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·M K WaldorL Steinman
Apr 3, 1999·Current Opinion in Oncology·R A Brodsky, B D Smith
Feb 24, 2005·Current Opinion in Oncology·Daniel B Drachman, Robert A Brodsky
Jul 22, 2014·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M NagappaA Mahadevan
Feb 5, 2008·Journal of Autoimmunity·Sean DeaneM Eric Gershwin
Sep 15, 2007·Journal of Neuroimmunology·Douglas E GladstoneThomas H Brannagan
Jun 24, 2008·Annals of the New York Academy of Sciences·Daniel B DrachmanRobert A Brodsky
Jul 1, 1988·Clinical Immunology and Immunopathology·S de SilvaD B Drachman
Nov 1, 1984·Annals of Neurology·A G Engel
Jan 1, 1987·Annals of the New York Academy of Sciences·K R McIntosh, D B Drachman
Aug 1, 1983·Annals of Neurology·A PestronkR N Adams
Jun 19, 2016·Current Research in Translational Medicine·P J KelseyJ A Snowden
Jul 18, 2008·Handbook of Clinical Neurology·Daniel B Drachman
Feb 1, 1985·Clinical Immunology and Immunopathology·D B DrachmanA Pestronk
Apr 18, 2000·Rheumatic Diseases Clinics of North America·R A BrodskyR J Jones
Apr 18, 1986·Science·K R McIntosh, D B Drachman